Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension.

Ricci GL, Melgosa MT, Burgos F, Valera JL, Pizarro S, Roca J, Rodriguez-Roisin R, Barberà JA.

Liver Transpl. 2007 Nov;13(11):1506-14.

2.

Acute and long-term effects of inhaled iloprost in portopulmonary hypertension.

Melgosa MT, Ricci GL, García-Pagan JC, Blanco I, Escribano P, Abraldes JG, Roca J, Bosch J, Barberà JA.

Liver Transpl. 2010 Mar;16(3):348-56. doi: 10.1002/lt.21997.

3.
4.

Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.

Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW.

Chest. 2006 Feb;129(2):417-25.

PMID:
16478861
5.

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension.

Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J.

Lancet. 1991 Nov 9;338(8776):1173-4.

PMID:
1682593
6.
7.

Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension.

Ribas J, Angrill J, Barberà JA, García-Pagán JC, Roca J, Bosch J, Rodriguez-Roisin R.

Eur Respir J. 1999 Jan;13(1):210-2.

8.

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.

Atz AM, Adatia I, Lock JE, Wessel DL.

J Am Coll Cardiol. 1999 Mar;33(3):813-9.

9.
10.

Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension.

Findlay JY, Harrison BA, Plevak DJ, Krowka MJ.

Liver Transpl Surg. 1999 Sep;5(5):381-7.

11.

Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance.

Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Mühling J, Dehne MG, Czeslick E.

Eur J Cardiothorac Surg. 2002 Nov;22(5):746-52.

PMID:
12414041
12.

Portopulmonary hypertension: an update.

Safdar Z, Bartolome S, Sussman N.

Liver Transpl. 2012 Aug;18(8):881-91. doi: 10.1002/lt.23485. Review.

13.
14.

Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation.

Fullerton DA, Jones SD, Jaggers J, Piedalue F, Grover FL, McIntyre RC Jr.

J Thorac Cardiovasc Surg. 1996 Apr;111(4):753-62; discussion 762-3.

15.

Long-term follow-up of portopulmonary hypertension patients after liver transplantation.

Khaderi S, Khan R, Safdar Z, Stribling R, Vierling JM, Goss JA, Sussman NL.

Liver Transpl. 2014 Jun;20(6):724-7. doi: 10.1002/lt.23870.

16.

Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.

Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M.

J Am Coll Cardiol. 1998 Oct;32(4):1068-73.

17.

Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms.

Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M.

Circulation. 2001 Jan 30;103(4):544-8.

18.

Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension.

Williamson DJ, Hayward C, Rogers P, Wallman LL, Sturgess AD, Penny R, Macdonald PS.

Circulation. 1996 Aug 1;94(3):477-82.

19.

Effects of inhaled prostacyclin as compared with inhaled nitric oxide in a canine model of pulmonary microembolism and oleic acid edema.

Zwissler B, Welte M, Habler O, Kleen M, Messmer K.

J Cardiothorac Vasc Anesth. 1995 Dec;9(6):634-40.

PMID:
8664452
20.

Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.

Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS.

Chest. 2001 Sep;120(3):866-72.

PMID:
11555522

Supplemental Content

Support Center